Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system
Authors:
Open Access
- 14 June 2025
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (6) , 1-9
Abstract
Purpose: This randomized, open-label, two-arm, parallel-group, single dose, multi-center phase I study (ClinicalTrials.gov ID, NCT05275010) investigated the comparability of the pharmacokinetics of a new formulation combining pertuzumab (P) and trastuzumab (H) in one fixed-dose combination for subcutaneous injection (FDC SC) using a proprietary on-body injector (OBI) or a handheld syringe with hypodermic needle in healthy male subjects. Methods: Healthy male subjects were randomized 1:1 to either PH FDC SC using a handheld syringe (Arm 1) or an OBI device (Arm 2). Co-primary endpoints were: (i) area under the time–concentration curve (AUC) from the start of dosing to day 63 (AUC0–62) of serum P, (ii) maximum serum concentration (Cmax) from start of dosing to 63 days of serum P, (iii) AUC from the start of dosing to day 63 (AUC0–62) of serum H, and (iv) Cmax from start of dosing to 63 days of serum H. Safety was a key secondary endpoint. Liquid chromatography coupled to tandem mass spectrometry was used to measure pertuzumab and trastuzumab simultaneously in serum samples. Results: The obtained geometric mean ratios for Cmax and AUC0–62 were within the pre-specified bioequivalence margins (0.80, 1.25) for both P and H, therefore meeting the criteria for bioequivalence. No discontinuations due to safety reasons were reported. Overall, the final safety analysis with longer follow-up was consistent with the primary analysis; there were no new or unexpected safety findings. Conclusion: This study demonstrated the feasibility of a hands-free device approach to deliver pertuzumab and trastuzumab in one fixed-dose combination for subcutaneous injection without compromising pharmacokinetics and safety.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 26 references indexed in Scilit:
- Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge GapClinical Pharmacology & Therapeutics, 2024
- Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerEuropean Journal of Cancer, 2022
- Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II studyEuropean Journal of Cancer, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of BiosimilarsDrugs, 2020
- 80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa studyAnnals of Oncology, 2020
- Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding StudyThe Journal of Clinical Pharmacology, 2018
- Subcutaneous delivery of monoclonal antibodies: How do we get there?Journal of Controlled Release, 2018
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and OpportunitiesBioDrugs, 2018
- Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesCancer Chemotherapy and Pharmacology, 2013